JP2014139182A - フィチン酸塩と亜鉛の一定量組み合わせ - Google Patents
フィチン酸塩と亜鉛の一定量組み合わせ Download PDFInfo
- Publication number
- JP2014139182A JP2014139182A JP2014023681A JP2014023681A JP2014139182A JP 2014139182 A JP2014139182 A JP 2014139182A JP 2014023681 A JP2014023681 A JP 2014023681A JP 2014023681 A JP2014023681 A JP 2014023681A JP 2014139182 A JP2014139182 A JP 2014139182A
- Authority
- JP
- Japan
- Prior art keywords
- phytate
- combination
- hydroxyapatite
- zinc
- calcification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 title claims abstract description 79
- 235000002949 phytic acid Nutrition 0.000 title claims abstract description 79
- 239000011701 zinc Substances 0.000 title claims abstract description 60
- 229910052725 zinc Inorganic materials 0.000 title claims abstract description 25
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims abstract description 23
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 54
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 53
- 238000002425 crystallisation Methods 0.000 claims abstract description 32
- 230000008025 crystallization Effects 0.000 claims abstract description 32
- 230000002308 calcification Effects 0.000 claims abstract description 22
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 18
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 210000004556 brain Anatomy 0.000 claims abstract description 6
- 210000002216 heart Anatomy 0.000 claims abstract description 4
- 210000004072 lung Anatomy 0.000 claims abstract description 4
- 210000001367 artery Anatomy 0.000 claims abstract description 3
- 210000003462 vein Anatomy 0.000 claims abstract description 3
- 239000004575 stone Substances 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 15
- 239000013078 crystal Substances 0.000 claims description 13
- 230000002195 synergetic effect Effects 0.000 claims description 10
- 239000002324 mouth wash Substances 0.000 claims description 6
- 238000010899 nucleation Methods 0.000 claims description 6
- 230000006911 nucleation Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 abstract description 20
- 210000003491 skin Anatomy 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 description 16
- 208000004434 Calcinosis Diseases 0.000 description 15
- 239000011575 calcium Substances 0.000 description 13
- 230000018109 developmental process Effects 0.000 description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 11
- 239000001506 calcium phosphate Substances 0.000 description 11
- 235000011010 calcium phosphates Nutrition 0.000 description 11
- 238000001556 precipitation Methods 0.000 description 11
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 11
- 229910052791 calcium Inorganic materials 0.000 description 10
- 229910000389 calcium phosphate Inorganic materials 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 210000003296 saliva Anatomy 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Diphosphoinositol tetrakisphosphate Chemical compound OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229920000388 Polyphosphate Polymers 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 210000001765 aortic valve Anatomy 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000001205 polyphosphate Substances 0.000 description 5
- 235000011176 polyphosphates Nutrition 0.000 description 5
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 4
- 208000006558 Dental Calculus Diseases 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 240000006909 Tilia x europaea Species 0.000 description 4
- 235000011941 Tilia x europaea Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000004571 lime Substances 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000002064 Dental Plaque Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 208000007565 gingivitis Diseases 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229940068041 phytic acid Drugs 0.000 description 3
- 239000000467 phytic acid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 239000011135 tin Substances 0.000 description 3
- 229910052718 tin Inorganic materials 0.000 description 3
- 206010006326 Breath odour Diseases 0.000 description 2
- 229910014572 C—O—P Inorganic materials 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000002882 anti-plaque Effects 0.000 description 2
- 238000001636 atomic emission spectroscopy Methods 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical class [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 2
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- -1 fluoride ions Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009616 inductively coupled plasma Methods 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000002667 nucleating agent Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000011885 synergistic combination Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CTPQAXVNYGZUAJ-UHFFFAOYSA-N (2-hydroxy-3,4,5,6-tetraphosphonooxycyclohexyl) dihydrogen phosphate Chemical compound OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O CTPQAXVNYGZUAJ-UHFFFAOYSA-N 0.000 description 1
- 0 *[C@]1[C@@](*)[C@](*)[C@@](*)[C@@](*)[C@@]1* Chemical compound *[C@]1[C@@](*)[C@](*)[C@@](*)[C@@](*)[C@@]1* 0.000 description 1
- 206010003173 Arterial rupture Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000008887 Dental Deposits Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- INAPMGSXUVUWAF-WWHKVMGRSA-N [(2s,3r,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@@H](O)[C@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-WWHKVMGRSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000002272 anti-calculus Effects 0.000 description 1
- 230000000170 anti-cariogenic effect Effects 0.000 description 1
- 230000003610 anti-gingivitis Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 150000004287 bisbiguanides Chemical class 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000004091 cariogenic agent Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003145 cytotoxic factor Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- HOXINJBQVZWYGZ-UHFFFAOYSA-N fenbutatin oxide Chemical compound C=1C=CC=CC=1C(C)(C)C[Sn](O[Sn](CC(C)(C)C=1C=CC=CC=1)(CC(C)(C)C=1C=CC=CC=1)CC(C)(C)C=1C=CC=CC=1)(CC(C)(C)C=1C=CC=CC=1)CC(C)(C)C1=CC=CC=C1 HOXINJBQVZWYGZ-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000006503 pathological mineralization Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- BRFMYUCUGXFMIO-UHFFFAOYSA-N phosphono dihydrogen phosphate phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(=O)OP(O)(O)=O BRFMYUCUGXFMIO-UHFFFAOYSA-N 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Catalysts (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Dental Preparations (AREA)
Abstract
Description
有機物:互いに結合してコロニーを形成している主として微生物(細菌、真菌など)に由来するが、口腔中に残った食物残渣に由来するものもある。
無機物:唾液中に存在するカルシウムとオルトリン酸塩から主としてなり、ヒドロキシアパタイト(HAP)と呼ばれる、結晶格子に配置されている。
本発明において「心血管の石」とは、血管壁または心臓の他の部分に蓄積された固体結石を意味するものとする。
(1)フィチン酸塩は同種および異種核形成ならびにヒドロキシアパタイトおよび他のリン酸カルシウムの結晶成長の極めて強力な阻害剤である。この作用の結果はヒドロキシアパタイトの結晶化の阻害であるが、同時に、歯に付着しているリン酸カルシウムの微粒子の発達も回避される。
(2)フィチン酸塩はヒトの唾液に見られ、その濃度は個人の食生活によって異なる。
(3)唾液にフィチン酸塩が不足している特定の個人は、舌下のヒドロキシアパタイト結石を示すことがある。
(4)フィチン酸塩は、他の直鎖ポリリン酸塩よりも唾液ホスファターゼの作用に対して耐性が高い、ヒト唾液中に存在する天然産物であるという利点がある。
(5)フィチン酸塩とZn2+の相乗作用的組み合わせは、フィチン酸塩単独の場合よりも、ヒドロキシアパタイトの結晶化の阻害に対してより有意なin vitro結果を示す。
ヒドロキシアパタイトの沈殿速度を研究するため、in vitro系を設計した。次のような実験条件を用いた系を使用した:[リン酸塩]=1.5mM、[Ca2+]=60mg/l、pH=7.5。ヒドロキシアパタイトの沈殿速度を、3mlプラスチックバイアルを用い、島津(UV−120−02)分光光度計にて、550nmで5分ごとの吸光度を記録することにより記録した。結果を図1に示す。ヒドロキシアパタイトの沈殿は、フィチン酸塩−Znの相乗作用的混合物で、モル比10:1を用いることで完全に阻害されたことが分かる。
実施例1と同様の系を用い、次のような実験条件を用いた:[リン酸塩]=2.5mM、[Ca2+]=60mg/l、pH=7.5。ヒドロキシアパタイトの沈殿速度を、3mlプラスチックバイアルを用い、島津(UV−120−02)分光光度計にて、550nmで5分ごとの吸光度を記録することにより記録した。結果を図2に示す。Zn単独では阻害作用は見られないことから、フィチン酸塩とZn2+の間には相乗作用が存在することが分かる。
12匹の雄ウィスターラット(体重およそ250g)(Harlan Iberica s.l., Barcelona, Spainより入手)を、温度および湿度条件をそれぞれ21±1℃および60±5%、明暗周期を12:12時間とした本発明者らの動物施設で7日間適応させた。ラットはPlexiglasケージで1ケージに2匹飼い、食物と水を自由に与えた。
まず、頬歯腔におけるヒドロキシアパタイトの形成に対するフィチン酸塩の作用を評価することにした。患者に、1日2回一方または他方の口内洗浄剤10mlを投与するという異なる2種類の処置を1週間施した(表1)。頬歯腔の石化付着物(mineralised deposits)に関する質的評価を行ったところ、歯石または歯の結石の目に見える有意な減少が示された。
次に、フィチン酸塩を欠き、Zn2+と組み合わせた口内洗浄剤を用い、15日後に、頬歯腔におけるヒドロキシアパタイトの付着物を量的に評価した。患者に、1日2回一方または他方の口内洗浄剤20mlを投与するという異なる2種類の処置を2週間施した(表2)。量的評価は頬歯腔の石化付着物に関して、患者からプラークおよび歯石の付着物を機械的に採取し、歯科臨床においてそれらをフィルター上で吸引し、その後、付着物中に存在するヒドロキシアパタイトを1M HClに溶解し、誘導結合プラズマ(Optima 5300DV)を用いた原子発光分光法により、カルシウムおよびリンを測定することにより行った。石化付着物においてリンでは95.1%、カルシウムでは88.3%の減少が見られた。
Claims (12)
- ヒドロキシアパタイトの結晶化の処置に用いられる、相乗作用的割合におけるフィチン酸塩と亜鉛との一定量組み合わせ。
- 前記組み合わせが4:1を超えるフィチン酸塩および亜鉛のモル比である、請求項1に記載のフィチン酸塩と亜鉛の一定量組み合わせ。
- 前記組み合わせが5:1のフィチン酸塩および亜鉛のモル比である、請求項1に記載のフィチン酸塩と亜鉛の一定量組み合わせ。
- 前記組み合わせが5:1を超えるフィチン酸塩および亜鉛のモル比である、請求項1に記載のフィチン酸塩と亜鉛の一定量組み合わせ。
- 歯の結石の処置、予防および/または回避用薬剤を製造するための、請求項1〜4のいずれか一項に記載の組み合わせの使用。
- 心血管石灰化の処置、予防および/または回避用薬剤を製造するための、請求項1〜5のいずれか一項に記載の組み合わせの使用。
- 前記心血管石灰化が、動脈、静脈および/または心臓において起こる、請求項6に記載の使用。
- 脳における石灰化の処置、予防および/または回避用薬剤を製造するための、請求項1〜4のいずれか一項に記載の組み合わせの使用。
- 肺における石灰化の処置、予防および/または回避用薬剤を製造するための、請求項1〜4のいずれか一項に記載の組み合わせの使用。
- 皮膚における石灰化の処置、予防および/または回避用薬剤を製造するための、請求項1〜4のいずれか一項に記載の組み合わせの使用。
- 口内洗浄剤を製造するための、請求項1〜4のいずれか一項に記載の組み合わせの使用。
- ヒドロキシアパタイトの核形成および結晶成長に対するフィチン酸塩の阻害作用の促進剤としての、請求項1〜11のいずれか一項に記載の組み合わせにおけるZn2+の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP-200600377 | 2006-02-17 | ||
ES200600377A ES2280136B1 (es) | 2006-02-17 | 2006-02-17 | Asociacion a dosis fija de fitato y zinc. |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008554771A Division JP5554499B2 (ja) | 2006-02-17 | 2007-02-14 | フィチン酸塩と亜鉛の一定量組み合わせ |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014139182A true JP2014139182A (ja) | 2014-07-31 |
JP2014139182A5 JP2014139182A5 (ja) | 2014-09-18 |
JP5908933B2 JP5908933B2 (ja) | 2016-04-26 |
Family
ID=38007006
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008554771A Expired - Fee Related JP5554499B2 (ja) | 2006-02-17 | 2007-02-14 | フィチン酸塩と亜鉛の一定量組み合わせ |
JP2014023681A Expired - Fee Related JP5908933B2 (ja) | 2006-02-17 | 2014-02-10 | フィチン酸塩と亜鉛の一定量組み合わせ |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008554771A Expired - Fee Related JP5554499B2 (ja) | 2006-02-17 | 2007-02-14 | フィチン酸塩と亜鉛の一定量組み合わせ |
Country Status (18)
Country | Link |
---|---|
US (2) | US8377908B2 (ja) |
EP (1) | EP1984001B1 (ja) |
JP (2) | JP5554499B2 (ja) |
CN (1) | CN101384266B (ja) |
AT (1) | ATE516035T1 (ja) |
AU (1) | AU2007216453B2 (ja) |
BR (1) | BRPI0707008A2 (ja) |
CA (1) | CA2641216C (ja) |
CY (1) | CY1111913T1 (ja) |
DK (1) | DK1984001T3 (ja) |
ES (1) | ES2280136B1 (ja) |
MX (1) | MX2008010502A (ja) |
NO (1) | NO341286B1 (ja) |
PL (1) | PL1984001T3 (ja) |
PT (1) | PT1984001E (ja) |
RU (1) | RU2415673C2 (ja) |
SI (1) | SI1984001T1 (ja) |
WO (1) | WO2007093611A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2280136B1 (es) * | 2006-02-17 | 2008-08-16 | Universitat De Les Illes Balears | Asociacion a dosis fija de fitato y zinc. |
MX339909B (es) * | 2011-07-12 | 2016-06-14 | Procter & Gamble | Composiciones para el cuidado bucal que comprende acido fitico. |
ES2486441B1 (es) * | 2014-04-02 | 2015-06-11 | Universitat De Les Illes Balears | Preparaciones combinadas de acidificantes urinarios e inhibidores de la cristalización y su aplicación para el tratamiento o prevención de la litiasis renal fosfática o inducida por fosfato cálcico |
CA2971579C (en) * | 2014-12-26 | 2022-10-04 | Colgate-Palmolive Company | Zinc phosphate complex for oral care |
DE102016013737A1 (de) | 2016-11-17 | 2018-05-17 | WindplusSonne GmbH | Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe |
CN108444985B (zh) * | 2018-04-25 | 2021-02-02 | 山西省食品药品检验所(山西省药品包装材料监测中心) | 一种肾精子icp-ms鉴别方法及应用 |
US11633416B1 (en) | 2020-03-06 | 2023-04-25 | Arcus Biosciences, Inc. | Oral formulations of CD73 compounds |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5622720A (en) * | 1979-07-31 | 1981-03-03 | Lion Corp | Composition for oral cavity application |
JPS5639008A (en) * | 1979-09-05 | 1981-04-14 | Lion Corp | Composition for oral cavity application |
JPS5645407A (en) * | 1979-09-20 | 1981-04-25 | Lion Corp | Composition for oral cavity application |
JPS6229526A (ja) * | 1985-08-01 | 1987-02-07 | Wakamoto Pharmaceut Co Ltd | 高カルシウム尿症の治療及び予防剤 |
JPS63139116A (ja) * | 1986-11-28 | 1988-06-10 | Lion Corp | 口腔用組成物 |
JPH01305033A (ja) * | 1988-06-01 | 1989-12-08 | Sanwa Kagaku Kenkyusho Co Ltd | 循環改善剤及び循環改善機能性食品並びにし好品 |
US5300289A (en) * | 1991-12-10 | 1994-04-05 | The Dow Chemical Company | Phytate antimicrobial compositions in oral care products |
JPH08104635A (ja) * | 1994-10-06 | 1996-04-23 | Ichimaru Pharcos Co Ltd | フィチン酸亜鉛を有効成分とする外用製剤 |
JPH10182383A (ja) * | 1996-12-24 | 1998-07-07 | Lion Corp | 口腔用組成物 |
JP2002542282A (ja) * | 1999-04-22 | 2002-12-10 | シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ | 栄養補助食品または薬物として有用な、カルニチンおよびリン酸イノシトール含有組成物 |
JP2004065249A (ja) * | 2002-06-13 | 2004-03-04 | Fumio Hara | フィチン酸、イノシトールおよびナイアシンの富化方法、食品の製造方法、並びに食品 |
WO2005044278A1 (en) * | 2003-11-07 | 2005-05-19 | Laboratorios Sanifit, S.L. | Myo-inositol hexaphosphate for topical use |
WO2007063507A2 (en) * | 2005-11-29 | 2007-06-07 | The Procter & Gamble Company | Dentifrice composition comprising binder system comprising hydrophilic clay material |
JP2009520829A (ja) * | 2005-12-20 | 2009-05-28 | ザ プロクター アンド ギャンブル カンパニー | 亜鉛およびフィチン酸塩を含む口腔ケア組成物 |
JP5554499B2 (ja) * | 2006-02-17 | 2014-07-23 | ウニベルシタット デ レス イリュス バレアルス | フィチン酸塩と亜鉛の一定量組み合わせ |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3934001A (en) | 1965-12-07 | 1976-01-20 | Lever Brothers Company | Oral compositions containing germicidally active plastic powders |
NL149701C (nl) | 1965-12-08 | 1981-05-15 | Procter & Gamble | Werkwijze voor het bereiden van een tegen tandsteen werkzaam tandverzorgingsmiddel, dat als werkzaam bestanddeel een fosfonzuurderivaat bevat, alsmede gevormd tandverzorgingsmiddel. |
US3934002A (en) | 1972-06-30 | 1976-01-20 | The Procter & Gamble Company | Oral compositions for plaque, caries and calculus retardation with reduced staining tendencies |
US4215105A (en) | 1978-10-27 | 1980-07-29 | Colgate-Palmolive Company | Anticalculus oral composition |
US4515772A (en) | 1982-06-22 | 1985-05-07 | The Procter & Gamble Company | Oral compositions |
US4808409A (en) | 1984-08-16 | 1989-02-28 | Board Of Trustees, University Of Illinois | Low cariogenic sweetening agents |
US4627977A (en) | 1985-09-13 | 1986-12-09 | Colgate-Palmolive Company | Anticalculus oral composition |
US4808401A (en) | 1985-09-13 | 1989-02-28 | Colgate-Palmolive Company | Anticalculus oral composition |
ES2007238A6 (es) * | 1988-06-17 | 1989-06-01 | Univ Illes Balears | Procedimiento para la preparacion de fitato-zn (ii)> |
US5286479A (en) * | 1991-12-10 | 1994-02-15 | The Dow Chemical Company | Oral compositions for suppressing mouth odors |
CN1102978A (zh) * | 1993-11-23 | 1995-05-31 | 姚焕新 | 多功能牙膏 |
CN1259033C (zh) | 2004-06-24 | 2006-06-14 | 江西航天日用化工发展有限责任公司 | 可去除烟黄斑牙垢的复方牙膏及其制备方法 |
-
2006
- 2006-02-17 ES ES200600377A patent/ES2280136B1/es active Active
-
2007
- 2007-02-14 BR BRPI0707008-0A patent/BRPI0707008A2/pt not_active Application Discontinuation
- 2007-02-14 CN CN200780005915XA patent/CN101384266B/zh not_active Expired - Fee Related
- 2007-02-14 PT PT07726369T patent/PT1984001E/pt unknown
- 2007-02-14 PL PL07726369T patent/PL1984001T3/pl unknown
- 2007-02-14 JP JP2008554771A patent/JP5554499B2/ja not_active Expired - Fee Related
- 2007-02-14 DK DK07726369.7T patent/DK1984001T3/da active
- 2007-02-14 RU RU2008138358/15A patent/RU2415673C2/ru not_active IP Right Cessation
- 2007-02-14 WO PCT/EP2007/051413 patent/WO2007093611A1/en active Application Filing
- 2007-02-14 SI SI200730738T patent/SI1984001T1/sl unknown
- 2007-02-14 EP EP07726369A patent/EP1984001B1/en active Active
- 2007-02-14 MX MX2008010502A patent/MX2008010502A/es active IP Right Grant
- 2007-02-14 CA CA2641216A patent/CA2641216C/en not_active Expired - Fee Related
- 2007-02-14 US US12/279,616 patent/US8377908B2/en active Active
- 2007-02-14 AU AU2007216453A patent/AU2007216453B2/en not_active Ceased
- 2007-02-14 AT AT07726369T patent/ATE516035T1/de active
-
2008
- 2008-09-11 NO NO20083901A patent/NO341286B1/no not_active IP Right Cessation
-
2011
- 2011-10-06 CY CY20111100955T patent/CY1111913T1/el unknown
-
2013
- 2013-02-19 US US13/770,782 patent/US9144578B2/en active Active
-
2014
- 2014-02-10 JP JP2014023681A patent/JP5908933B2/ja not_active Expired - Fee Related
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5622720A (en) * | 1979-07-31 | 1981-03-03 | Lion Corp | Composition for oral cavity application |
JPS5639008A (en) * | 1979-09-05 | 1981-04-14 | Lion Corp | Composition for oral cavity application |
JPS5645407A (en) * | 1979-09-20 | 1981-04-25 | Lion Corp | Composition for oral cavity application |
JPS6229526A (ja) * | 1985-08-01 | 1987-02-07 | Wakamoto Pharmaceut Co Ltd | 高カルシウム尿症の治療及び予防剤 |
JPS63139116A (ja) * | 1986-11-28 | 1988-06-10 | Lion Corp | 口腔用組成物 |
JPH01305033A (ja) * | 1988-06-01 | 1989-12-08 | Sanwa Kagaku Kenkyusho Co Ltd | 循環改善剤及び循環改善機能性食品並びにし好品 |
US5300289A (en) * | 1991-12-10 | 1994-04-05 | The Dow Chemical Company | Phytate antimicrobial compositions in oral care products |
JPH07501827A (ja) * | 1991-12-10 | 1995-02-23 | ザ ダウ ケミカル カンパニー | 口の医療製品におけるフィチン酸−抗菌組成物 |
JPH08104635A (ja) * | 1994-10-06 | 1996-04-23 | Ichimaru Pharcos Co Ltd | フィチン酸亜鉛を有効成分とする外用製剤 |
JPH10182383A (ja) * | 1996-12-24 | 1998-07-07 | Lion Corp | 口腔用組成物 |
JP2002542282A (ja) * | 1999-04-22 | 2002-12-10 | シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ | 栄養補助食品または薬物として有用な、カルニチンおよびリン酸イノシトール含有組成物 |
JP2004065249A (ja) * | 2002-06-13 | 2004-03-04 | Fumio Hara | フィチン酸、イノシトールおよびナイアシンの富化方法、食品の製造方法、並びに食品 |
WO2005044278A1 (en) * | 2003-11-07 | 2005-05-19 | Laboratorios Sanifit, S.L. | Myo-inositol hexaphosphate for topical use |
JP2007510710A (ja) * | 2003-11-07 | 2007-04-26 | ラボラトリオス、サニフィト、ソシエダッド、リミターダ | 局所用のミオイノシトール6リン酸 |
WO2007063507A2 (en) * | 2005-11-29 | 2007-06-07 | The Procter & Gamble Company | Dentifrice composition comprising binder system comprising hydrophilic clay material |
JP2009519235A (ja) * | 2005-11-29 | 2009-05-14 | ザ プロクター アンド ギャンブル カンパニー | 親水性粘土材を含む結合剤系を備える歯磨剤組成物 |
JP2009520829A (ja) * | 2005-12-20 | 2009-05-28 | ザ プロクター アンド ギャンブル カンパニー | 亜鉛およびフィチン酸塩を含む口腔ケア組成物 |
JP5554499B2 (ja) * | 2006-02-17 | 2014-07-23 | ウニベルシタット デ レス イリュス バレアルス | フィチン酸塩と亜鉛の一定量組み合わせ |
Also Published As
Publication number | Publication date |
---|---|
RU2008138358A (ru) | 2010-03-27 |
SI1984001T1 (sl) | 2011-12-30 |
ES2280136A1 (es) | 2007-09-01 |
MX2008010502A (es) | 2008-10-23 |
US20090035232A1 (en) | 2009-02-05 |
NO20083901L (no) | 2008-09-11 |
AU2007216453B2 (en) | 2012-09-27 |
PT1984001E (pt) | 2011-10-18 |
ATE516035T1 (de) | 2011-07-15 |
JP5908933B2 (ja) | 2016-04-26 |
ES2280136B1 (es) | 2008-08-16 |
JP2009526818A (ja) | 2009-07-23 |
JP5554499B2 (ja) | 2014-07-23 |
EP1984001B1 (en) | 2011-07-13 |
US9144578B2 (en) | 2015-09-29 |
WO2007093611A1 (en) | 2007-08-23 |
US8377908B2 (en) | 2013-02-19 |
CA2641216C (en) | 2014-04-15 |
CN101384266A (zh) | 2009-03-11 |
AU2007216453A1 (en) | 2007-08-23 |
US20140056994A1 (en) | 2014-02-27 |
DK1984001T3 (da) | 2011-11-07 |
BRPI0707008A2 (pt) | 2011-04-12 |
PL1984001T3 (pl) | 2012-02-29 |
NO341286B1 (no) | 2017-10-02 |
EP1984001A1 (en) | 2008-10-29 |
CN101384266B (zh) | 2013-03-20 |
CY1111913T1 (el) | 2015-11-04 |
CA2641216A1 (en) | 2007-08-23 |
RU2415673C2 (ru) | 2011-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5908933B2 (ja) | フィチン酸塩と亜鉛の一定量組み合わせ | |
Cochrane et al. | New approaches to enhanced remineralization of tooth enamel | |
Divyapriya et al. | Casein phosphopeptide-amorphous calcium phosphate in dentistry: An update | |
Grohe et al. | Advanced non-fluoride approaches to dental enamel remineralization: The next level in enamel repair management | |
JP2006199702A (ja) | 過飽和溶液中のカルシウムおよびリン酸イオンからなるうがい薬 | |
JP7053542B2 (ja) | スフィンゴシン系化合物による材料の保護 | |
Polat et al. | Overview of current fluorine-free remineralization materials and methods as an alternative to topical fluoride: An up-to-date | |
Wesselink et al. | Theinnfluenceoof 1-hydroxyethylidene-1, 1-bisphosphonate (HEBP) on dental root resorption in the mouse | |
JP2010507622A (ja) | アルキルリン酸エステル類の新規用途 | |
Jindal et al. | Reverse the adverse: A review | |
CA3114810A1 (en) | Silicic acids for use in the treatment of periodontitis | |
DS | Effect of water Clove extract on the microhardness and microscopic features of initial caries-like lesion of permanent teeth, compared to fluoridated agent | |
Mellberg et al. | Fluoride concentrations in deciduous teeth of children using fluoride mouthrinses | |
JP2007099632A (ja) | 歯牙の再石灰化促進方法 | |
Larkina et al. | Investigation of calcium-and hyaluronic acid-containing drugs osteoplastic activity in rats with periodontitis | |
Naji | Materials Used in Remineralization of Initial Caries | |
JPS61233612A (ja) | チユ−インガム | |
Qiu et al. | The combination of arginine and fluoride-containing bioactive glass acted synergistically in inhibiting enamel demineralization in permanent teeth | |
Kaur et al. | Neoteric Non-Fluoride Enamel Remineralization Systems: A Review | |
Ingram et al. | Calcium salt precipitation and mechanisms of inhibition under oral conditions | |
RU2380081C2 (ru) | Состав для лечения и профилактики заболеваний полости рта | |
Fleisch | Department of Pathophysiology, University, 3010 Bern, Switzerland | |
Lai | Reduction in dental caries incidence through tropical stannous flouride | |
Efka et al. | PREVENTION OF WHITE SPOT LESIONS DURING ORTHODONTIC TREATMENT | |
JPH11171749A (ja) | 口腔用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140801 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150317 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150617 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150717 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160301 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160324 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5908933 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |